Initial Assessment of Desmoid Tumors and Treatment Planning

Dr. Gounder introduces the program focusing on advancing sarcoma care with emphasis on emerging data and evolving treatment strategies for desmoid tumors. He is joined by Dr. Atrayee Basu Mallick and Dr. Nam Bui to discuss latest advances and their implications for patient selection and clinical decision-making.

Dr. Basu Mallick outlines her systematic approach to newly diagnosed desmoid tumor patients, beginning with comprehensive history-taking to identify potential familial adenomatous polyposis connections and physical examination focusing on tumor location and palpability. Critical assessment factors include symptom burden, tumor growth trajectory, and impact on daily living activities.

She emphasizes obtaining objective growth assessments by having patients describe size changes using familiar comparisons like fruit sizes rather than vague descriptors. Both physical and psychological impacts require evaluation, as patients often experience significant anxiety following biopsy-confirmed diagnoses.

Key decision-making factors include tumor location (head/neck and mesenteric areas representing high-risk sites), proximity to neurovascular structures, size criteria (tumors exceeding 5 to 6 centimeters having higher likelihood of requiring therapy), and symptom severity. However, shared decision-making remains paramount, with some patients choosing watchful waiting even for progressive disease when asymptomatic.

Dr. Bui emphasizes the individualized, case-by-case approach necessary for desmoid tumor management. He notes that up to 20% of tumors may spontaneously regress, though identifying these patients prospectively remains impossible. This uncertainty influences monitoring strategies and treatment timing decisions.

Local therapies like cryoablation have emerged as alternatives to surgery, though patient selection depends heavily on tumor location and anatomical considerations. Both panelists stress the importance of colonoscopy screening for potential familial adenomatous polyposis unless definitive genetic testing excludes APC mutations.